Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats

(2009) Silke Retlich et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside

(2009) Marc Vanderheyden et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

(2009) J. Rosenstock et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

(2009) Joshua J. Neumiller   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice

(2009) Nancy Bohannon   POSTGRADUATE MEDICINE

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis

(2008) M. Bodmer et al.   DIABETES CARE

Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

(2008) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

(2008) S. Hüttner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis

(2007) Matteo Monami et al.   DIABETES RESEARCH AND CLINICAL PRACTICE